Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations.
about
Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administrationEvolution of stimulants to treat ADHD: transdermal methylphenidateADHD in Children Onset of Efficacy of Long-Acting Psychostimulants in Pediatric Attention-Deficit/Hyperactivity DisorderTwo CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basisA Review of Pharmacological Management of Attention-Deficit/Hyperactivity DisorderMethylphenidate use in pregnancy and lactation: a systematic review of evidenceFrom Clinical Application to Cognitive Enhancement: The Example of MethylphenidateAn open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics.Lisdexamfetamine dimesylate: the first prodrug stimulant.Pharmacological Treatment of ADHD in Addicted Patients: What Does the Literature Tell Us?Methylphenidate HCl: therapy for attention deficit hyperactivity disorder.Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder.New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder.Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics.The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder.A randomized placebo-controlled double-blind study evaluating the time course of response to methylphenidate hydrochloride extended-release capsules in children with attention-deficit/hyperactivity disorder.Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin(®)) in healthy adult volunteers.Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study.Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind StudyTransdermal and oral dl-methylphenidate-ethanol interactions in C57BL/6J mice: transesterification to ethylphenidate and elevation of d-methylphenidate concentrationsTreating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications.A novel HPLC fluorescence method for the quantification of methylphenidate in human plasmaApplication of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in AdultsEnantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping.Absorption Differences between Immediate-Release Dexmethylphenidate and dl-Methylphenidate.Dexmethylphenidate extended-release capsules for the treatment of attention deficit hyperactivity disorder.Targeting the dopamine system in the treatment of attention-deficit/hyperactivity disorder.Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoproteinDexmethylphenidate hydrochloride in the treatment of attention deficit hyperactivity disorder.Osmotic release oral system-methylphenidate improves neural activity during low reward processing in children and adolescents with attention-deficit/hyperactivity disorder.A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.Effects of oral methamphetamine on cocaine use: a randomized, double-blind, placebo-controlled trial.Association of dopamine transporter gene variants with childhood ADHD features in bipolar disorder.Methylphenidate for Treating ADHD: A Naturalistic Clinical Study of Methylphenidate Blood Concentrations in Children and Adults With Optimized Dosage.Methylphenidate: established and expanding roles in symptom management.ADHD and delinquency--a developmental perspective.Metabolic, toxicological, and safety considerations for drugs used to treat ADHD.Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.An evaluation of the pharmacokinetics of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder.A pharmacokinetic evaluation of oral edivoxetine hydrochloride for the treatment of attention deficit-hyperactivity disorder.
P2860
Q22241466-114D7606-4DB7-444E-8513-E8FEDEC020ECQ22252903-A14DA48E-E2D4-4173-808F-0B0F4669091BQ22305481-438B9684-BCBA-4328-BAEC-3D1A63EDF367Q24655643-B1E3082A-7CD7-4BE2-A2D6-014B91BA4B67Q26741896-92C113A7-DCD5-4C93-AD28-02B9F229A660Q26851791-B65EF20D-021A-4862-8115-83A0417E953FQ28073785-BD27E823-6B6D-4E2C-A9BC-F09058815D48Q33819929-20C75ED3-98A3-4C9A-9247-AE97F4ADF683Q33894687-E9F9518A-6376-4FCF-89F9-58314A101F23Q33919950-84A54C49-2C7B-44D1-B345-CDA0448F23F1Q34424163-CD13EE93-83BE-402D-9BB8-3ABE3E3512B6Q34434809-85863111-4755-48FC-863B-447431228729Q34468658-8A5096CB-9720-48B4-A466-0B0DA603BEB6Q34576973-A7E6AC39-24DC-4BA3-832A-57748CD2D0CDQ34673021-126F895B-6C2F-4DF5-B026-E1E6156E7740Q34719188-FC3E8A84-BC3A-4291-8877-06831247A0FAQ34719368-AA74188C-1F26-4F4B-A964-DA5EFD3EA759Q34752064-799B357B-F9E1-4E92-BF41-12DD5A89AEA6Q35588067-A401B3F8-1106-4028-860F-98838AA8BC36Q35600580-CDB1DAB4-325D-4500-AEC2-C3740B515C18Q35833310-3E7CC6D9-A111-4DD7-BDFC-39AAE7676943Q36130918-EBF0ACA5-9DA0-4364-95D7-3A9AD2B8DF70Q36159334-4BA64F24-B018-4DB3-808C-E83795837D88Q36596952-3548D42F-3ED4-4386-ACBB-F7AFEC4EDF44Q36618684-BF151D58-7069-4387-B2E0-CCFE0A80F5E9Q36675408-5CE91676-9D72-4A25-AEDF-1E4247ABE91FQ36787333-34CBF7D2-DA8F-418B-8D13-0632D3278C9CQ37137438-10A6108D-4FFC-41DA-B473-29B822E6EFECQ37166164-5CCA3431-F843-4040-8130-4003867FE6BAQ37184589-798D696C-841A-4934-B120-C736373DEEDCQ37190656-06146CDF-829F-4CDC-9E8F-DB57E8200839Q37343634-44BB32EC-45A0-4132-A9FC-35CEAE1E4035Q37523029-CD5F1F48-57FE-4458-98E4-BFF3A77AD07BQ37685508-A6569810-ECF0-42C5-BCC6-FBA8E1C50844Q37965133-B0491F43-9A8F-4726-B1BE-AB718D70D63FQ37988784-EFDF0032-B131-4E57-8BA8-75026987EBD7Q37993127-EF987732-58B7-4987-847E-905C26BAA950Q38011640-B710B3C5-0602-43EB-AAA6-DA6CC333A242Q38214174-FE141BF5-5EA9-4145-A84F-A9F31DE8C4A1Q38229065-F9EA920E-32FF-400C-A4A7-3681AABFC907
P2860
Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Advances in the pharmacotherap ...... methylphenidate formulations.
@ast
Advances in the pharmacotherap ...... methylphenidate formulations.
@en
Advances in the pharmacotherap ...... methylphenidate formulations.
@nl
type
label
Advances in the pharmacotherap ...... methylphenidate formulations.
@ast
Advances in the pharmacotherap ...... methylphenidate formulations.
@en
Advances in the pharmacotherap ...... methylphenidate formulations.
@nl
prefLabel
Advances in the pharmacotherap ...... methylphenidate formulations.
@ast
Advances in the pharmacotherap ...... methylphenidate formulations.
@en
Advances in the pharmacotherap ...... methylphenidate formulations.
@nl
P2093
P2860
P921
P1433
P1476
Advances in the pharmacotherap ...... methylphenidate formulations.
@en
P2093
Arthur B Straughn
John S Markowitz
Kennerly S Patrick
P2860
P304
P356
10.1592/PHCO.23.12.1281.32697
P407
P577
2003-10-01T00:00:00Z